The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Convergent antibody responses to SARS-CoV-2 in convalescent individuals
Open accessPublished version of a preprint
Abstract
During the coronavirus disease-2019 (COVID-19) pandemic, severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) has led to the infection of millions of people and has claimed hundreds of thousands of lives. The entry of the virus into cells depends on the receptor-binding domain (RBD) of the spike (S) protein of SARS-CoV-2. Although there is currently no vaccine, it is likely that antibodies will be essential for protection. However, little is known about the human antibody response to SARS-CoV-2 1-5. Here we report on 149 COVID-19-convalescent individuals. Plasma samples collected an average of 39 days after the onset of symptoms had variable half-maximal pseudovirus neutralizing titres; titres were less than 50 in 33% of samples, below 1,000 in 79% of samples and only 1% of samples had titres above 5,000. Antibody sequencing revealed the expansion of clones of RBD-specific memory B cells that expressed closely related antibodies in different individuals. Despite low plasma titres, antibodies to three distinct epitopes on the RBD neutralized the virus with half-maximal inhibitory concentrations (IC 50 values) as low as 2 ng ml-1. In conclusion, most convalescent plasma samples obtained from individuals who recover from COVID-19 do not contain high levels of neutralizing activity. Nevertheless, rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The magnitude of these NAb responses appear to correlate with viral load, with higher responses reported in patients with more severe disease, and in older adults compared with younger adults26–29.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In agreement with previous reports3,6,9, there was a broad range of plasma neutralizing activity 3–14 weeks after the second vaccine dose that was similar to that elicited by natural infection in a convalescent cohort after 1.3 months, and greater than the activity at 6.2 months after infection (Fig. 1a, Extended Data Table 1).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SARS-CoV-2 infection rapidly elicits nAbs (16, 21–24) that decline, but remain detectable, over several months (25–29).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Spike is the target of SARS-CoV-2 neutralizing antibodies, and the receptor binding domain (RBD) of Spike is the target of >90% of neutralizing antibodies in COVID-19 cases (Brouwer et al., 2020; Piccoli et al., 2020; Robbiani et al., 2020; Rogers et al., 2020; Suthar et al., 2020), with some neutralizing antibodies instead targeting the N-terminal domain (NTD) (Liu et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Robbiani et al., 2020
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although it is unclear how long protective effects last beyond the first few months after vaccination, some studies suggest that the elicited neutralizing activity is maintained for up to 8 months after the natural infection with SARS-CoV-2 (refs. 41,42).”
From Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy (2021) · cites this paper as [41]
Experimental — accuracy not yet measured
In the citing paper
“8 weeks after the second vaccine injection volunteers showed high levels of IgM, and IgG anti-SARS-CoV-2 spike protein (S) and receptor binding domain (RBD) binding titers3,5,6.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [6]
In the citing paper
“In line with previous reports3,6,9, IgG and IgM levels were significantly higher in the vaccinated group compared to a cohort of convalescent patients assayed 1.3 and 6.2 months after infection, while IgA levels were similar (Extended Data Fig 1j–l).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [6]
In the citing paper
“We limited our analysis to RBD because plasma RBD antibodies are strongly correlated with neutralizing activity3,10–12.”
From Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection (2021) · cites this paper as [3]
In the citing paper
“Consistent with this observation, there was an overall increase in the apparent avidity of plasma antibodies between 1.3 and 12 months3,4 (P < 0.0001) (Extended Data Fig. 7c).”
From Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection (2021) · cites this paper as [3]
In the citing paper
“In contrast to the earlier time point, 13 of 15 neutralizing antibodies obtained after 12 months interfered only with C121, a class 2 antibody3,23 (Fig. 4c, Extended Data Fig. 9).”
From Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection (2021) · cites this paper as [3]
In the citing paper
“Most serum nAb responses elicited during natural infection are directed at the RBD (21, 23, 30, 31).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [23]
In the citing paper
“Numerous neutralizing anti-RBD monoclonal antibodies (mAbs) have been characterized, the most potent of which block the RBD-ACE2 interaction (16, 17, 22–24, 32–37).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [23]
In the citing paper
“Analyses of the B cell responses to the spike generally focus on the RBD and on cells sorted with RBD baits introducing an inherent bias by omitting non-RBD targets”
From SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 (2021) · cites this paper as Robbiani et al., 2020
In the citing paper
“The neutralizing antibodies are produced by B cells with a wide range of heavy chain and light chain V genes (Robbiani et al., 2020; Rogers et al., 2020). SARS-CoV-2 neutralizing antibodies also exhibit little to no somatic hypermutation (Gaebler et al., 2020; Robbiani et al., 2020; Rogers et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Robbiani et al., 2020
In the citing paper
“Although neutralizing antibody titers have not correlated with reduced COVID-19 severity (Dan et al., 2021; Piccoli et al., 2020; Robbiani et al., 2020), SARS-CoV-2 cTfh cell frequencies have been associated with reduced disease severity (Rydyznski Moderbacher et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Robbiani et al., 2020
In the citing paper
“This appears to hold true in the case of SARS-CoV-2, where neutralizing antibody titers (and total Spike antibody titers) have positively correlated with COVID-19 disease severity in large cohort studies (Piccoli et al., 2020; Robbiani et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Robbiani et al., 2020
In the citing paper
“However, it should also be noted that circulating SARS-CoV-2 neutralizing antibody titers are relatively low in a substantial fraction of recovered COVID-19 cases (Dan et al., 2021; Robbiani et al., 2020; Wajnberg et al., 2020), indicating that either the neutralizing antibody potency or the serum concentration is suboptimal in this subset.”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Robbiani et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A simple method for displaying the hydropathic character of a protein
Kyte, J., & Doolittle, R. F. (1982) · Journal of Molecular Biology · doi:10.1016/0022-2836(82)90515-0 · Cited by 22,927
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination
Punjani, A., Rubinstein, J. L., Fleet, D. J., & Brubaker, M. A. (2017) · Nature Methods · doi:10.1038/nmeth.4169 · Cited by 11,626
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Automated electron microscope tomography using robust prediction of specimen movements
Mastronarde, D. N. (2005) · Journal of Structural Biology · doi:10.1016/j.jsb.2005.07.007 · Cited by 5,136
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
Adachi, A., Gendelman, H. E., Koenig, S., Folks, T. M., Willey, R. L., Rabson, A. B., & Martín, M. Á. (1986) · Journal of Virology · doi:10.1128/jvi.59.2.284-291.1986 · Cited by 2,805
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885
A serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769
Correlates of protection induced by vaccination
Plotkin, S. A. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00131-10 · Cited by 1,745
Cited by
Sorted by citations
Items 701–800 of 1,017
Siracusano, G., Brombin, C., Pastori, C., Cugnata, F., Noviello, M., Tassi, E., Princi, D., Cantoni, D. M., Malnati, M., Maugeri, N., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.772239 · Cited by 29
Asano, M., Okada, H., Itoh, Y., Hirata, H., Ishikawa, K., Yoshida, E., Matsui, A., Kelly, E. J., Shoemaker, K., Olsson, U., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.10.030 · Cited by 29
Akter, A., Ahmed, T., Tauheed, I., Akhtar, M., Rahman, S. I. A., Khaton, F., Ahmmed, F., Ferdous, J., Afrad, M. H., Kawser, Z., et al. (2022) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0010102 · Cited by 29
Peng, H. T., Rhind, S. G., & Beckett, A. (2021) · JMIR Public Health and Surveillance · doi:10.2196/25500 · Cited by 29
Greaney, A. J., Eguia, R. T., Starr, T. N., Khan, K., Franko, N., Logue, J. K., Lord, S. M., Speake, C., Chu, H. Y., Sigal, A., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010592 · Cited by 29
Scharf, L., Axelsson, H., Emmanouilidi, A., Mathew, N. R., Sheward, D. J., Leach, S., Isakson, P., Smirnov, I. V., Marklund, E., Miron, N., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.165299 · Cited by 29
Jensen, J. L., Sankhala, R. S., Dussupt, V., Bai, H., Hajduczki, A., Lal, K. G., Chang, W. C., Martinez, E. J., Peterson, C. E., Golub, E. S., et al. (2023) · Journal of Virology · doi:10.1128/jvi.01596-22 · Cited by 29
Molecular mechanisms of COVID-19-induced pulmonary fibrosis and epithelial-mesenchymal transition
Pi, P., Zeng, Z., Zeng, L., Han, B., Bai, X., & Xu, S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1218059 · Cited by 29
Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice
Cohen, A. A., Gnanapragasam, P. N. P., Lee, Y. E., Hoffman, P. R., Ou, S. K.-H., Kakutani, L. M., Keeffe, J. R., Wu, H., Howarth, M. R., West, A. P., et al. (2021) · CaltechAUTHORS (California Institute of Technology) · Cited by 29
Self-citationIvanova, E. N., Shwetar, J., Devlin, J. C., Buus, T. B., Gray-Gaillard, S. L., Koide, A., Cornelius, A. R., Samanovic, M. I., Herrera, A. M., Mimitou, E. P., et al. (2021) · medRxiv · doi:10.1101/2021.04.20.21255677 · Cited by 29
Antibody Profiling of COVID-19 Patients in an Urban Low-Incidence Region in Northern Germany
Solbach, W., Schiffner, J., Backhaus, I., Burger, D., Staiger, R., Tiemer, B., Bobrowski, A., Hutchings, T., & Mischnik, A. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.570543 · Cited by 28
Barrett, E. S., Horton, D. B., Roy, J., Xia, W., Greenberg, P. J., Andrews, T., Gennaro, M. L., Parmar, V., Russell, W. D., Reilly, N., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa534 · Cited by 28
Xu, X. P., Nie, S., Wang, Y., Long, Q., Zhu, H., Zhang, X., Sun, J., Zeng, Q., Zhao, J., Liu, L., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00611-6 · Cited by 28
Gededzha, M. P., Mampeule, N., Jugwanth, S., Zwane, N., David, A., Burgers, W. A., Blackburn, J. M., Grove, J. S., George, J. A., Sanne, I., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252317 · Cited by 28
Wagner, A., Guzek, A., Ruff, J., Jasińska, J., Scheikl, U., Zwazl, I., Kundi, M., Stockinger, H. S. J., Farcet, M. R., Kreil, T. R., et al. (2021) · Communications Medicine · doi:10.1038/s43856-021-00012-4 · Cited by 28
Horton, D. B., Barrett, E. S., Roy, J., Gennaro, M. L., Andrews, T., Greenberg, P. J., Bruiners, N., Datta, P., Ukey, R., Velusamy, S. K., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab411 · Cited by 28
Shinnakasu, R., Sakakibara, S., Yamamoto, H. H., Wang, P.-H., Moriyama, S., Sax, N., Ono, C., Yamanaka, A., Adachi, Y., Onodera, T., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20211003 · Cited by 28
Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?
Zhang, J., Zhang, H., & Sun, L. (2022) · mAbs · doi:10.1080/19420862.2022.2031483 · Cited by 28
Wang, H., Yan, D., Li, Y., Gong, Y., Mai, Y., Li, B., Zhu, X., Wan, X., Xie, L., Jiang, H., et al. (2022) · Infectious Diseases of Poverty · doi:10.1186/s40249-022-00940-w · Cited by 28
de Souza, A. S., Amorim, V. M. D. F., Guardia, G. D. A., dos Santos, F. F., Ulrich, H., Galante, P. A. F., de Souza, R. F., & Guzzo, C. R. (2022) · Viruses · doi:10.3390/v14040827 · Cited by 28
Post-vaccination and post-infection humoral immune response to the SARS-CoV-2 infection
Andreev, I. V., Nechay, K. O., Andreev, A. I., Zubaryova, A. P., Esaulova, D. R., Alenova, A. M., Ia, N., Chernyavskaya, O. P., Lomonosov, K. S., Евгеньевич, Ш. А., et al. (2022) · Immunologiya · doi:10.33029/0206-4952-2022-43-1-18-32 · Cited by 28
Davenport, B., Catala, A., Weston, S. M., Johnson, R. M., Ardanuy, J., Hammond, H., Dillen, C. A., Frieman, M. B., Catalano, C. E., & Morrison, T. E. (2022) · npj Vaccines · doi:10.1038/s41541-022-00481-1 · Cited by 28
Cruz-Cárdenas, J. A., Gutiérrez, M., López-Arredondo, A., Castañeda‐Delgado, J. E., Rojas‐Martínez, A., Nakamura, Y., Enciso‐Moreno, J. A., Palomares, L. A., & Brunck, M. E. G. (2022) · Scientific Reports · doi:10.1038/s41598-022-22921-7 · Cited by 28
Tracking B cell responses to the SARS-CoV-2 mRNA-1273 vaccine
de Assis, F. L., Hoehn, K. B., Zhang, X., Kardava, L., Smith, C. D., Merhebi, O. E., Buckner, C. M., Trihemasava, K., Wang, W., Seamon, C. A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112780 · Cited by 28
Ivanova, E. N., Shwetar, J., Devlin, J. C., Buus, T. B., Gray-Gaillard, S. L., Koide, A., Cornelius, A. R., Samanovic, M. I., Herrera, A. M., Mimitou, E. P., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108572 · Cited by 28
Graham, C., Seow, J., Huettner, I., Khan, H., Kouphou, N., Acors, S., Winstone, H., Pickering, S., Galao, R. P., Lista, M. J., et al. (2021) · doi:10.1101/2021.02.03.429355 · Cited by 27
McConnell, S. A., & Casadevall, A. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01150-9 · Cited by 27
Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients
Ruétalo, N., Businger, R., Althaus, K., Fink, S., Ruoff, F., Pogoda, M., Iftner, A., Ganzenmueller, T., Hamprecht, K., Flehmig, B., et al. (2021) · mSphere · doi:10.1128/msphere.01145-20 · Cited by 27
Vitamin D and immuno-pathology of COVID-19: many interactions but uncertain therapeutic benefits
Banerjee, A., Ganguly, U., Saha, S., Chakrabarti, S., Saini, R. V., Rawal, R. K., Saso, L., & Chakrabarti, S. (2021) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1905519 · Cited by 27
Coronavirus infection: An immunologists' perspective
Sanctis, J. B. D., García, A. H., Moreno, D., & Hajdúch, M. (2021) · Scandinavian Journal of Immunology · doi:10.1111/sji.13043 · Cited by 27
Comparative Analysis of Antigen-Specific Anti–SARS-CoV-2 Antibody Isotypes in COVID-19 Patients
Fujigaki, H., Inaba, M., Osawa, M., Moriyama, S., Takahashi, Y., Suzuki, T., Yamase, K., Yoshida, Y., Yagura, Y., Oyamada, T., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001369 · Cited by 27
Grudlewska‐Buda, K., Wiktorczyk-Kapischke, N., Wałecka-Zacharska, E., Kwiecińska-Piróg, J., Buszko, K., Leis, K., Juszczuk, K., Gospodarek-Komkowska, E., & Skowron, K. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10091962 · Cited by 27
SARS-CoV-2 cell entry and targeted antiviral development
Chen, Z., Du, R., Achi, J. G., Rong, L., & Cui, Q. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.007 · Cited by 27
Vandergaast, R., Carey, T. S., Reiter, S., Lathrum, C., Lech, P. J., Gnanadurai, C. W., Haselton, M., Buehler, J., Narjari, R., Schnebeck, L., et al. (2021) · mSphere · doi:10.1128/msphere.00170-21 · Cited by 27
Parrott, J. C., Annibale, A. M., Vassor, V. E., Osahan, S., Hsin, Y., Sanderson, M., Fernandez, S., Seligson, A. L., Hughes, S., Wu, J., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab296 · Cited by 27
Lamikanra, A., Nguyen, D. V., Peter Simmonds, K., Williams, S. V., Bentley, E. M., Rowe, C., Otter, A. D., Brooks, T. J. G., Gilmour, K. C., Mai, A., et al. (2021) · Transfusion · doi:10.1111/trf.16600 · Cited by 27
Hardy, O. J., Dubourg, D., Bourguignon, M., Dellicour, S., Eggerickx, T., Gilbert, M., Sanderson, J., Scohy, A., Vandael, E., & Decroly, J.-M. (2021) · Demographic Research · doi:10.4054/demres.2021.45.33 · Cited by 27
Nanoplasmonic multiplex biosensing for COVID-19 vaccines
Funari, R., Fukuyama, H., & Shen, A. Q. (2022) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2022.114193 · Cited by 27
Skrzat‐Klapaczyńska, A., Bieńkowski, C., Kowalska, J. D., Paciorek, M., Puła, J., Krogulec, D., Stengiel, J., Pawełczyk, A., Perlejewski, K., Osuch, S., et al. (2022) · Vaccines · doi:10.3390/vaccines10040552 · Cited by 27
Hallmarks of Severe COVID-19 Pathogenesis: A Pas de Deux Between Viral and Host Factors
Rovito, R., Augello, M., Ben-Haim, A., Bono, V., Monforte, A. D., & Marchetti, G. C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.912336 · Cited by 27
Molecular analysis of a public cross-neutralizing antibody response to SARS-CoV-2
Yuan, M., Wang, Y., Lv, H., Tan, T. J. C., Wilson, I. A., & Wu, N. C. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111650 · Cited by 27
Zhao, F., Yuan, M., Keating, C., Shaabani, N., Limbo, O., Joyce, C., Woehl, J. L., Barman, S., Burns, A., Tran, Q., et al. (2023) · Science Signaling · doi:10.1126/scisignal.abk3516 · Cited by 27
Kutsuna, S., Asai, Y., Matsunaga, A., Kinoshita, N., Terada, M., Miyazato, Y., Nakamoto, T., Suzuki, T., Saito, S., Endo, M., et al. (2021) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2021.01.006 · Cited by 27
Ehling, R. A., Weber, C. R., Mason, D. M., Friedensohn, S., Wagner, B., Bieberich, F., Kapetanovic, E., Vazquez-Lombardi, R., Roberto, R. B. D., Hong, K., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110242 · Cited by 27
Structural basis of Omicron neutralization by affinity-matured public antibodiesPreprint
Sheward, D. J., Pushparaj, P., Das, H., Kim, C., Kim, S., Hanke, L., Dyrdak, R., McInerney, G. M., Albert, J., Murrell, B., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.03.474825 · Cited by 27
Lubin, J. H., Markosian, C., Balamurugan, D., Ma, M. T., Chen, C.-H., Liu, D., Pasqualini, R., Arap, W., Burley, S. K., & Khare, S. D. (2023) · JCI Insight · doi:10.1172/jci.insight.168296 · Cited by 26
Lenart, K., Cerveira, R. A., Hellgren, F., Ols, S., Sheward, D. J., Kim, C., Cagigi, A., Gagné, M., Davis, B. J., Germosen, D., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00806-2 · Cited by 26
Gabernet, G., Marquez, S., Bjornson, R. D., Peltzer, A., Meng, H., Aron, E., Lee, N. Y., Jensen, C. G., Ladd, D., Polster, M., et al. (2024) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1012265 · Cited by 26
Paschold, L., Simnica, D., Willscher, E., Vehreschild, M. J. G. T., Dutzmann, J., Sedding, D., Schultheiß, C., & Binder, M. (2020) · Journal of Clinical Investigation · doi:10.1172/jci142966 · Cited by 26
Convalescent Plasma-Mediated Resolution of Covid-19 in Humoral Immunodeficiency
Honjo, K., Russell, R. M., Li, R., Liu, W., Stoltz, R., Tabengwa, E. M., Hua, Y., Prichard, L. E., Kornbrust, A., Sterrett, S., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100164 · Cited by 26
Self-citationCross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses
Bullen, G., Galson, J. D., Hall, G., Villar, P., Moreels, L., Ledsgaard, L., Mattiuzzo, G., Bentley, E. M., Masters, E. W., Tang, D. G., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.678570 · Cited by 26
The Emergence of SARS-CoV-2 within the Dog Population in Croatia: Host Factors and Clinical Outcome
Stevanović, V., Tabain, I., Vilibić‐Čavlek, T., Maurić, M., Benvin, I., Hruškar, Ž., Kovač, S., Šmit, I., Miletić, G., Hađina, S., et al. (2021) · Viruses · doi:10.3390/v13081430 · Cited by 26
Factors Affecting the Antibody Immunogenicity of Vaccines against SARS-CoV-2: A Focused Review
Cheng, Z. J., Xue, M., Zheng, P., Lyu, J., Zhan, Z., Hu, H., Zhang, Y., Zhang, X. D., & Sun, B. (2021) · Vaccines · doi:10.3390/vaccines9080869 · Cited by 26
Zou, S., Wu, M., Ming, F., Wu, S., Guo, W., Marley, G., Xing, Z., Zhang, Z., Zeng, M., Sun, C., et al. (2022) · AIDS Research and Therapy · doi:10.1186/s12981-022-00459-y · Cited by 26
Rabaan, A. A., Al-Ahmed, S. H., Albayat, H., Alwarthan, S. M., Alhajri, M. M., Najim, M. A., Alshehail, B. M., Al-Adsani, W., Alghadeer, A., Abduljabbar, W. A., et al. (2023) · Medicina · doi:10.3390/medicina59030507 · Cited by 26
Takano, T., Sato, T., Kotaki, R., Moriyama, S., Fukushi, S., Shinoda, M., Kabasawa, K., Shimada, N., Kousaka, M., Adachi, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37128-1 · Cited by 26
Dynamics of anti-SARS-CoV-2 IgG antibodies post-COVID-19 in a Brazilian Amazon population
Bichara, C. D. A., Amoras, E. D. S. G., Vaz, G. L., Torres, M. K. D. S., Queiroz, M. A. F., do Amaral, I. P. C., Vallinoto, I. M. V. C., Bichara, C. N. C., & Vallinoto, A. C. R. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06156-x · Cited by 26
Potential SARS-CoV-2 vaccines: Concept, progress, and challenges
Hosseini, S. A., Zahedipour, F., Mirzaei, H., & Oskuee, R. K. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107622 · Cited by 26
Konrath, K. M., Liaw, K., Wu, Y., Zhu, X., Walker, S. N., Xu, Z., Schultheis, K., Chokkalingam, N., Chawla, H., Du, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110318 · Cited by 26
A potent synthetic nanobody targets RBD and protects mice from SARS-CoV-2 infectionPreprint
Li, T., Cai, H., Yao, H., Zhou, B., Zhang, N., Gong, Y., Zhao, Y., Shen, Q., Qin, W., Hutter, C. A. J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.09.143438 · Cited by 26
Steffen, T. L., Stone, E. T., Hassert, M., Geerling, E., Grimberg, B. T., Espino, A. M., Pantoja, P., Climent, C., Hoft, D. F., George, S. L., et al. (2020) · doi:10.1101/2020.08.21.261727 · Cited by 25
Tada, T., Zhou, H., Dcosta, B. M., Samanovic, M. I., Cornelius, A. R., Herati, R. S., Mulligan, M. J., & Landau, N. R. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110237 · Cited by 25
Sangesland, M., Yousif, A. S., Ronsard, L., Kazer, S. W., Zhu, A. L., Gatter, G. J., Hayward, M. R., Barnes, R. M., Quirindongo-Crespo, M., Rohrer, D., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108065 · Cited by 25
Zaichuk, T. A., Nechipurenko, Y. D., Adzhubey, A. A., Оникиенко, С. Б., Черешнев, В. А., Zainutdinov, S. S., Kochneva, G. V., Sv, N., & Matveeva, O. V. (2020) · Molecular Biology · doi:10.1134/s0026893320060151 · Cited by 25
Takagi, A., & Matsui, M. (2020) · Journal of Virology · doi:10.1128/jvi.01837-20 · Cited by 25
Early and long term antibody kinetics of asymptomatic and mild disease COVID-19 patients
Efrati, S., Catalogna, M., Hamed, R. A., Hadanny, A., Bar‐Chaim, A., Benveniste‐Levkovitz, P., Strugo, R., & Levtzion‐Korach, O. (2021) · Scientific Reports · doi:10.1038/s41598-021-93175-y · Cited by 25
Community engagement during COVID: A field report from seven CTSAs
Marsh, E. E., Kappelman, M. D., Kost, R. G., Mudd‐Martin, G., Shannon, J., Stark, L. A., & Carrasquillo, O. (2021) · Journal of Clinical and Translational Science · doi:10.1017/cts.2021.785 · Cited by 25
Self-citationShalash, A. O., Hussein, W. M., Skwarczyński, M., & Tóth, I. (2021) · Advanced Science · doi:10.1002/advs.202100985 · Cited by 25
Xu, K., An, Y., Li, Q., Huang, W., Han, Y., Zheng, T., Fang, F., Liu, H., Liu, C., Gao, P., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1959270 · Cited by 25
Cell therapy strategies for COVID-19: Current approaches and potential applications
Zaki, M. M., Lesha, E., Said, K., Kiaee, K., Robinson‐McCarthy, L. R., George, H., Hanna, A., Appleton, E., Liu, S., Ng, A. H. M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg5995 · Cited by 25
Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera
Hu, J., Wei, X., Jin, X., Peng, P., Xu, F.-L., Wu, K., Luo, F., Jin, A., Fang, L., Liu, B., et al. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.11.007 · Cited by 25
Autoimmune Effect of Antibodies against the SARS-CoV-2 Nucleoprotein
Matyushkina, D. S., Shokina, V., Tikhonova, P., Manuvera, V. A., Shirokov, D. A., Kharlampieva, D. D., Лазарев, В. Н., Varizhuk, A. M., Vedekhina, T., Pavlenko, A. V., et al. (2022) · Viruses · doi:10.3390/v14061141 · Cited by 25
Li, R., Mor, M., Ma, B., Clark, A. E., Alter, J., Werbner, M., Lee, J. C., Leibel, S. L., Carlin, A. F., Dessau, M., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03739-5 · Cited by 25
Hua, Q., Zhang, H., Yao, P., Xu, N., Sun, Y., Lu, H.-J., Xu, F., Liao, Y., Yang, J., Mao, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.939311 · Cited by 25
Rovito, R., Bono, V., Augello, M., Tincati, C., Mainoldi, F., Beaudoin-Bussières, G., Tauzin, A., Bianchi, S., Hadla, M., Yellenki, V., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-23923-1 · Cited by 25
Ding, D., Wen, Y., Liao, C.-M., Yin, X., Zhang, R., Wang, J., Zhou, S., Zhang, Z.-M., Zou, Y.-K., Gao, X.-F., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01642 · Cited by 25
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
Mast, F. D., Navare, A., van der Sloot, A. M., Coulombe‐Huntington, J., Rout, M. P., Baliga, N. S., Kaushansky, A., Chait, B. T., Aderem, A. A., Rice, C. M., et al. (2020) · The Journal of Cell Biology · doi:10.1083/jcb.202006159 · Cited by 25
Self-citationSARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis
Berardis, S., Verroken, A., Vetillart, A., Struyf, C., Gilbert, M., Gruson, D., & Gohy, S. (2020) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2020.08.005 · Cited by 24
Viruses That Can and Cannot Coexist With Humans and the Future of SARS-CoV-2
Furuse, Y., & Oshitani, H. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.583252 · Cited by 24
Noh, J. Y., Kwak, J.-E., Yang, J., Hwang, S. Y., Yoon, J. G., Seong, H., Hyun, H., Lim, C. S., Yoon, S., Ryou, J., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab124 · Cited by 24
Immunodominant antibody germlines in COVID-19
Andreano, E., & Rappuoli, R. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20210281 · Cited by 24
Longitudinal SARS-CoV-2 antibody study using the Easy Check COVID-19 IgM/IgG™ lateral flow assay
Higgins, R. L., Rawlings, S. A., Case, J., Lee, F., Chan, C. W., Barrick, B. L., Burger, Z. C., Yeo, K.-T. J., & Marrinucci, D. C. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247797 · Cited by 24
SARS-CoV-2: Pathogenesis, Molecular Targets and Experimental Models
Kanimozhi, G., Bharathiraja, P., Pawar, C. S., Khan, H. A., Alrokayan, S., & Prasad, N. R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.638334 · Cited by 24
Structure-guided antibody cocktail for prevention and treatment of COVID-19
Su, S.-C., Yang, T., Yu, P., Liang, K.-H., Wy, C., Yang, C.-W., Lin, H.-T., Wang, M.-J. S., Lu, R., Tso, H.-C., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009704 · Cited by 24
Schmitz, A., Weber, A., Bayin, M., Breuers, S., Fieberg, V., Famulok, M., & Mayer, G. (2021) · Angewandte Chemie · doi:10.1002/ange.202100316 · Cited by 24
Altomare, C. G., Adelsberg, D. C., Carreño, J. M., Sapse, I. A., Amanat, F., Ellebedy, A. H., Simon, V. R., Krammer, F., & Bajic, G. (2022) · mBio · doi:10.1128/mbio.03580-21 · Cited by 24
MacDonald, M., Weathered, R. K., Stewart, E. C., Magold, A. I., Mukherjee, A., Gurbuxani, S. K., Smith, H., McMullen, P., Mueller, J. S., Husain, A. N., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007798 · Cited by 24
Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens
Wang, Z., Muecksch, F., Münn, F., Cho, A., Zong, S., Raspe, R., Ramos, V., Johnson, B., Tanfous, T. B., DaSilva, J., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20220826 · Cited by 24
Self-citationSøndergaard, J. N., Tulyeu, J., Edahiro, R., Shirai, Y., Yamaguchi, Y., Murakami, T., Morita, T., Kato, Y., Hirata, H., Takeda, Y., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2217902120 · Cited by 24
Yu, H., Liu, B., Zhang, Y., Gao, X., Wang, Q., Xiang, H., Peng, X., Xie, C., Wang, Y., Hu, P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36761-0 · Cited by 24
Multi-omics for COVID-19: driving development of therapeutics and vaccines
Guo, M., Xiong, M., Peng, J., Guan, T., Su, H., Huang, Y., Yang, C., Li, Y., Boraschi, D., Pillaiyar, T., et al. (2023) · National Science Review · doi:10.1093/nsr/nwad161 · Cited by 24
Huang, R., Jenkins, G. W., Kim, Y., Stanfield, R. L., Singh, A., Martinez‐Yamout, M. A., Kroon, G. J. A., Torres, J. L., Jackson, A. M., Kelley, A., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2303455120 · Cited by 24
de Campos‐Mata, L., Trinité, B., Modrego, A., Vaquero, S. T., Pradenas, E., Pons-Grífols, A., Melero, N. R., Carlero, D., Marfil, S., Santiago, C. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45171-9 · Cited by 24
Hartley, G. E., Fryer, H. A., Gill, P. A., Boo, I., Bornheimer, S. J., Hogarth, P. M., Drummer, H. E., O’Hehir, R. E., Edwards, E. S. J., & van Zelm, M. C. (2024) · npj Vaccines · doi:10.1038/s41541-024-00919-8 · Cited by 24
Fu, X., Tao, L., & Zhang, X. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.12.007 · Cited by 24
Human antiviral B cell responses: Emerging lessons from hepatitis B and COVID‐19
Burton, A. R., & Maini, M. K. (2021) · Immunological Reviews · doi:10.1111/imr.12953 · Cited by 24
Ragan, I. K., Hartson, L., Dutt, T. S., Obregón‐Henao, A., Maison, R. M., Gordy, P., Fox, A. C., Karger, B. R., Cross, S. T., Kapuscinski, M. L., et al. (2021) · Vaccines · doi:10.3390/vaccines9040340 · Cited by 24
Egia‐Mendikute, L., Bosch, A., Prieto‐Fernández, E., Lee, S. Y., Jiménez-Lasheras, B., Río, A. G.-D., Antoñana-Vildosola, A., Bruzzone, C., Bizkarguenaga, M., Embade, N., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02011-6 · Cited by 24
Peptide Antidotes to SARS-CoV-2 (COVID-19)Preprint
Watson, A., Ferreira, L. M. R., Hwang, P. K., Xu, J., & Stroud, R. M. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.06.238915 · Cited by 24
Metadata
- Authors
- Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., Hägglöf, T., Oliveira, T. Y., Viant, C., Hurley, A., Hoffmann, H.-H., Millard, K. G., Kost, R. G., Cipolla, M., Gordon, K., Bianchini, F., Chen, S. T., Ramos, V., Patel, R., Dizon, J., Shimeliovich, I., Mendoza, P., Hartweger, H., Nogueira, L., Pack, M., Horowitz, J., Schmidt, F., Weisblum, Y., Michailidis, E., Ashbrook, A. W., Waltari, E., Pak, J. E., Huey-Tubman, K. E., Koranda, N., Hoffman, P. R., West, A. P., Rice, C. M., Hatziioannou, T., Bjorkman, P. J., Bieniasz, P. D., Caskey, M., & Nussenzweig, M. C.
- Affiliations
- Institute for Research in Biomedicine (CH)
- Rockefeller University (US)
- California Institute of Technology (US)
- Chan Zuckerberg Biohub San Francisco (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Robbiani, Davide F.
- Bieniasz, Paul D.
- Caskey, Marina
- Nussenzweig, Michel C.
- ORCID
- Robbiani, Davide F.
- Gaebler, Christian
- Muecksch, Frauke
- Lorenzi, Julio C. C.
- Wang, Zijun
- Cho, Alice
- Agudelo, Marianna
- Barnes, Christopher O.
- Gazumyan, Anna
- Finkin, Shlomo
- Hägglöf, Thomas
- Oliveira, Thiago Y.
- Viant, Charlotte
- Hurley, Arlene
- Hoffmann, Hans-Heinrich
- Millard, Katrina G.
- Kost, Rhonda G.
- Cipolla, Melissa
- Bianchini, Filippo
- Chen, Spencer T.
- Dizon, Juan
- Shimeliovich, Irina
- Mendoza, Pilar
- Hartweger, Harald
- Nogueira, Lilian
- Schmidt, Fabian
- Weisblum, Yiska
- Michailidis, Eleftherios
- Ashbrook, Alison W.
- Waltari, Eric
- Pak, John E.
- Koranda, Nicholas
- Hoffman, Pauline R.
- West, Anthony P.
- Rice, Charles M.
- Bjorkman, Pamela J.
- Bieniasz, Paul D.
- Caskey, Marina
- Nussenzweig, Michel C.
- Venue
- Nature
- Published
- 2020-06-18
- Volume
- 584
- Issue
- 7821
- Pages
- 437-442
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC7442695
- OpenAlex
- W3036386821
- Cited by
- 1,853
- References
- 47
- Citations by year
- 2026: 49 · 2025: 79 · 2024: 115 · 2023: 194 · 2022: 403 · 2021: 691 · 2020: 321
- FWCI
- 52.98
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- PubMed Central (submittedVersion, cc-by-nc-nd)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute (UL1TR001866)
- George Mason University
- California Institute of Technology
- Fast Grants
- National Institutes of Health (P01-AI138398-S1, AI150464, TR001866, UL1TR001866)
- Beckman Institute, California Institute of Technology
- National Institute of Allergy and Infectious Diseases (R01AI091707, R01AI078788, P50AI150464, U19AI111825, P01AI138938, R37AI064003, T32AI070084)
- National Center for Advancing Translational Sciences (TR001866)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Keywords
- SARS-CoV-2, COVID-19 pandemic, convalescent plasma, neutralizing antibodies, receptor binding domain, spike protein, antibody response, memory B cells, pseudovirus neutralization, vaccine design, antibody epitopes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
